Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.9500
+0.02652.87%
Post-market: 0.97860.0286+3.01%19:20 EDT
Volume:387.40K
Turnover:368.75K
Market Cap:102.60M
PE:-3.33
High:0.9645
Open:0.9207
Low:0.9207
Close:0.9235
52wk High:1.51
52wk Low:0.3258
Shares:108.00M
Float Shares:106.00M
Volume Ratio:0.72
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.2881
ROE:-769.06%
ROA:-111.21%
PB:1233.03
PE(LYR):-3.30

Loading ...

Oncolytics Biotech Inc - to Launch Controlled Study in Second-Line Kras-Mutant Mss Mcrc With Interim Data Expected by End of 2026

THOMSON REUTERS
·
Feb 04

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)

TIPRANKS
·
Jan 22

Oncolytics Biotech Director Bernd R. Seizinger Reports Acquisition of Common Shares

Reuters
·
Jan 21

Oncolytics Biotech Inc. Held Special Shareholder Meeting

Reuters
·
Jan 16

Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Yujun Wu as Head of Biostatistics

Reuters
·
Jan 14

Lake Street Reaffirms Their Buy Rating on Oncolytics Biotech (ONCY)

TIPRANKS
·
Jan 13

Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial

Reuters
·
Jan 12

Oncolytics Biotech Inc - Four of 14 Third-Line Patients Achieved Objective Responses

THOMSON REUTERS
·
Jan 12

Oncolytics Biotech® Announces Updated Clinical Data From Goblet Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

THOMSON REUTERS
·
Jan 12

Oncolytics Biotech Inc - Plans Type C Meeting With FDA in Q1 2026

THOMSON REUTERS
·
Jan 12

Oncolytics Biotech Inc - Median Duration of Response About 17 Months

THOMSON REUTERS
·
Jan 12

Oncolytics Biotech Inc - Proposes Change of Incorporation to Nevada

THOMSON REUTERS
·
Jan 09

Oncolytics Biotech Shareholders to Vote on Proposal to Change Incorporation Jurisdiction to Nevada at Upcoming Special Meeting

Reuters
·
Jan 09

Lake Street Remains a Buy on Oncolytics Biotech (ONCY)

TIPRANKS
·
Jan 09

BRIEF-Oncolytics Biotech® Provides Update On Intellectual Property Strategy And Patent Filings

Reuters
·
Jan 08

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

THOMSON REUTERS
·
Jan 08

Oncolytics Biotech Inc - Plans Additional Patent Applications for Pelareorep

THOMSON REUTERS
·
Jan 08

Oncolytics Biotech Expands GI Tumor Advisory Board with Three New Experts

Reuters
·
Jan 07

Oncolytics Biotech Inc. Files Initial Statement of Beneficial Ownership for Allison Hagerman, VP of Product Development

Reuters
·
Jan 03

Oncolytics Biotech Inc. Files Initial Statement of Beneficial Ownership for CFO Kirk Look

Reuters
·
Jan 03